ICONIC Australian health brand CSL, which started life as Commonwealth Serum Laboratories, is this year celebrating 25 years listed on the Australian Securities Exchange (ASX).
Speaking at the 2019 CSL Annual General Meeting this week, Chairman, Brian McNamee, told shareholders, "the world has changed dramatically" in that time and "CSL has changed with it".
Highlighting the positive financial year dividend result which was up 18% in AU$ terms (PD 15 Aug), McNamee recognised company CEO and MD Paul Perreault and his management team for their leadership.
"CSL has a presence in almost 70 countries globally and employs more than 25,000 people," he said.
"We have in our stable some of the brightest and most educated minds within the scientific and business communities alike.
"This year we had a 13% growth in our employee base - a testament to the promising futures we offer our employees and job-seekers alike."
Covering off a reference to instabilities in the world political landscape, McNamee explained that in anticipation of Brexit, CSL has established "a new quality release laboratory in Amsterdam to allow Seqirus to seamlessly deliver vaccines across Europe".
He went on to identify four company strategic pillars:
1. People and culture
2. Growth
3. Efficiency, and
4. Public Health.
McNamee reaffirmed the company's commitment to retaining corporate headquarters and the company global R&D hub in Australia.
He also reminded investors that CSL's global corporate head office is to be relocated into the heart of the Melbourne Biomedical Precinct as announced in Aug (PD 09 Aug).
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Oct 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Oct 19
